Danaher Co. to Post Q2 2024 Earnings of $1.56 Per Share, Leerink Partnrs Forecasts (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Investment analysts at Leerink Partnrs cut their Q2 2024 earnings per share estimates for Danaher in a research report issued on Tuesday, April 23rd. Leerink Partnrs analyst P. Souda now expects that the conglomerate will post earnings of $1.56 per share for the quarter, down from their previous estimate of $1.66. The consensus estimate for Danaher’s current full-year earnings is $7.64 per share. Leerink Partnrs also issued estimates for Danaher’s Q2 2025 earnings at $1.87 EPS, Q3 2025 earnings at $1.94 EPS and Q4 2025 earnings at $2.64 EPS.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.36 earnings per share.

Several other analysts have also recently weighed in on the company. Raymond James boosted their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their price target for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Bank of America boosted their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $270.00.

Danaher Stock Up 0.3 %

Shares of NYSE DHR opened at $246.45 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a market cap of $182.54 billion, a price-to-earnings ratio of 41.77, a PEG ratio of 4.19 and a beta of 0.83. Danaher has a 12 month low of $182.09 and a 12 month high of $259.00. The stock has a 50-day moving average price of $248.87 and a two-hundred day moving average price of $231.08.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date was Wednesday, March 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insiders Place Their Bets

In other Danaher news, EVP Joakim Weidemanis sold 22,433 shares of the stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the transaction, the executive vice president now directly owns 90,412 shares in the company, valued at approximately $22,644,589.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Walter G. Lohr sold 3,289 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total transaction of $826,032.35. Following the transaction, the director now directly owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joakim Weidemanis sold 22,433 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $250.46, for a total value of $5,618,569.18. Following the transaction, the executive vice president now directly owns 90,412 shares in the company, valued at $22,644,589.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 106,565 shares of company stock worth $26,641,364. Corporate insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

A number of institutional investors have recently modified their holdings of the company. ST Germain D J Co. Inc. raised its position in shares of Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after purchasing an additional 41 shares during the period. Godsey & Gibb Inc. raised its position in shares of Danaher by 3.0% during the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after purchasing an additional 42 shares during the period. Nicholas Hoffman & Company LLC. raised its position in Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after buying an additional 43 shares during the last quarter. Berger Financial Group Inc raised its position in Danaher by 1.7% in the 4th quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after buying an additional 43 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its position in Danaher by 1.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after buying an additional 43 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.